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Summary
We have identified a novel fibroblast growth factor re-
ceptor 3 (FGFR3) missense mutation in four unrelated
individuals with skeletal dysplasia that approaches the
severity observed in thanatophoric dysplasia type I
(TD1). However, three of the four individuals developed
extensive areas of acanthosis nigricans beginning in early
childhood, suffer from severe neurological impairments,
and have survived past infancy without prolonged life-
support measures. The FGFR3 mutation (A1949T:
Lys650Met) occurs at the nucleotide adjacent to the TD
type II (TD2) mutation (A1948G: Lys650Glu) and re-
sults in a different amino acid substitution at a highly
conserved codon in the kinase domain activation loop.
Transient transfection studies with FGFR3 mutant con-
structs show that the Lys650Met mutation causes a dra-
matic increase in constitutive receptor kinase activity,
approximately three times greater than that observed
with the Lys650Glu mutation. We refer to the phenotype
caused by the Lys650Met mutation as “severe achon-
droplasia with developmental delay and acanthosis ni-
gricans” (SADDAN) because it differs significantly from
the phenotypes of other known FGFR3 mutations.
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Introduction
Fibroblast growth factor receptors (FGFRs) comprise a
family of structurally related tyrosine kinases (FGFRs
1–4) encoded by four distinct genes. These receptors
interact with a large group of ligands known as fibro-
blast growth factors (FGFs), leading to receptor acti-
vation and initiation of several different intracellular sig-
naling pathways. FGF/FGFR signaling is known to play
important roles in many diverse biological processes dur-
ing embryonic development and in mature organisms
(for reviews, see Basilico and Moscatelli 1992; Johnson
and Williams 1993). Recent genetic studies have estab-
lished that missense mutations in FGFRs 1, 2, and 3
cause several autosomal dominant human skeletal dys-
plasias and craniosynostosis syndromes and, in some of
these cases, dermatological disorders.
Recurrent mutations in the FGFR3 gene were discov-
ered first in achondroplasia, the most common genetic
form of short-limbed dwarfism in humans (Rousseau et
al. 1994; Shiang et al. 1994). Subsequent work has
shown that several other human skeletal dysplasias with
more-severe (thanatophoric dysplasia types I and II
[TD1 and TD2][Tavormina et al. 1995b]) or less-severe
(hypochondroplasia [Bellus et al. 1995b]) phenotypes
are also caused by specific point mutations in the FGFR3
gene. Common phenotypic features observed in all these
disorders include short stature with rhizomelic short-
ening of the extremities, brachydactyly, macrocephaly,
short vertebral pedicles, and narrowing of lumbar in-
terpedicular distances (Rimoin and Lachman 1993). Al-
though it first appeared that all FGFR3 mutations were
associated with skeletal dysplasia, subsequent work has
identified other missense mutations that result in cran-
iosynostosis with normal stature (i.e., Crouzon syn-
drome with acanthosis nigricans (Meyers et al. 1995)
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and Muenke craniosynostosis (Bellus et al. 1996a;
Muenke et al. 1997).
TD is a sporadically occurring lethal skeletal dyspla-
sia, which, based on clinical and molecular criteria, has
been further divided into two types—TD1 and TD2
(Langer et al. 1987; Tavormina et al. 1995b). TD1 is
characterized by short curved femurs with variable (but
usually absent) craniosynostosis and severe disturbances
of the growth plates. TD2, in contrast, is characterized
by straight femurs, invariant craniosynostosis (often clo-
verleaf skull), and relative preservation of the growth
plate (Langer et al. 1987; Norman et al. 1992). Further
genetic studies have revealed that TD1 may be caused
by as many as 10 distinct FGFR3 missense mutations.
Five TD1 mutations result in specific cysteine substitu-
tions in the extracellular domain of the receptor (Ta-
vormina et al. 1995a, 1995b; Rousseau et al. 1996). The
other five mutations eliminate the stop codon and result
in translation of a 141–amino acid C-terminal extension
(Rousseau et al. 1995; Bellus et al. 1997). In contrast,
FGFR3 mutations in TD2 (Tavormina et al. 1995a),
achondroplasia (Rousseau et al. 1994; Shiang et al.
1994; Bellus et al. 1995a) and hypochondroplasia (Bel-
lus et al. 1995b, 1996b; Prinos et al. 1995) all result
from mutations at specific nucleotides leading to unique
amino acid substitutions in the receptor protein.
Recent studies have shown that the FGFR3 mutations
causing achondroplasia (Gly380Arg), TD2 (Lys650Glu),
and TD1(Arg248Cys) lead to ligand-independent, con-
stitutive activation of the FGFR3 receptor and that the
degree of activation correlates directly with the severity
of the associated skeletal phenotype (Naski et al. 1996;
Webster and Donoghue 1996; Webster et al. 1996).
These data are supported by the phenotype of the
FGFR3 knockout mouse, which exhibits overgrowth of
the proximal long bones and vertebral bodies (Deng et
al. 1996; Colvin et al. 1996), and are consistent with
clinical observations that individuals with homozygous
achondroplasia and compound heterozygosity for
achondroplasia and hypochondroplasia have more-se-
vere skeletal phenotypes than simple heterozygotes (Hall
et al. 1969; McKusick et al. 1973). Together, these data
suggest that a normal function of FGFR3 is to inhibit
bone growth and that increasing amounts of inappro-
priate FGFR3 activity lead to more-severe skeletal
dysplasia.
Genetic analyses have been performed on many pa-
tients with these forms of skeletal dysplasia, but muta-
tions have not been found for all affected individuals
(Bellus et al. 1995a; Tavormina et al. 1995b) and rare
patients have phenotypes of intermediate severity be-
tween the recognized disorders (Bellus et al. 1995a;
Nishimura et al. 1995; Superti-Furga et al. 1995). Such
cases may represent variable expressivity of a common
mutation or may represent novel uncommon mutations
such as the FGFR3 Gly375Cys mutation in achondro-
plasia with atypical radiological findings (Nishimura et
al. 1995; Superti-Furga et al. 1995). We describe here
the discovery of a unique recurrent FGFR3 mutation in
four unrelated individuals with previous diagnoses of
severe achondroplasia or TD1. None exhibit craniosy-
nostosis, and three survived past infancy without the
need for prolonged ventilator support. The surviving pa-
tients have severe developmental delay and developed
acanthosis nigricans as infants or toddlers. The mutation
(A1949T: Lys650Met) occurs at the nucleotide adjacent
to the TD2 mutation (A1948G: Lys650Glu) within the
receptor tyrosine kinase domain activation loop and pre-
dicts a lysine-to-methionine substitution at codon 650.
Using in vitro transfection studies, we demonstrate that
the Lys650Met mutation results in strong constitutive
activation of FGFR3 receptor protein kinase activity.
Material and Methods
Patients and Cell Lines
Three of the four patients were evaluated either at the
medical genetics clinics at Johns Hopkins University
Hospital or at the University of Utah Health Sciences
Center. Informed consent for participation in genetic
testing was obtained through the parents of each affected
individual. Fibroblast and lymphoblast cell lines from
the fourth patient were provided by the International
Skeletal Dysplasia Registry.
PCR Amplification
DNA was isolated from blood leukocytes or lympho-
blast and fibroblast cell lines derived from affected in-
dividuals or their parents by standard methods. PCR
amplification of FGFR3 sequence was carried out as fol-
lows. In three patients, a 334-bp amplicon containing
FGFR3 exon 15, intron 15, and flanking regions of in-
tron 14 and exon 16 was defined by the forward primer
5′-AGGTGTGGGTGGAGTAGGCTG-3′ and the reverse
primer 5′-CTCAGGCGCCATCCACTTCAC-3′. PCR re-
actions were performed in a total volume of 50 ml con-
taining 1X PCR buffer (Perkin Elmer: 10 mM Tris, pH
8.3, 50 mM KCl), 10% dimethyl sulfoxide, 250 mM each
nucleotide (Pharmacia), and 2 U Taq DNA polymerase
(Perkin Elmer). PCR reactions were done in a Hybaid
Omnigene thermocycler with the following thermal cy-
cling program: 94 for 5 min; 35 cycles of 94 for 30 s,
64 for 45 s, and 72 for 45 s; and a final cycle of 72
for 10 min. DNA from a lymphoblast cell line derived
from the other patient was PCR amplified with primer
sequences and cycling conditions described elsewhere, to
amplify FGFR3 exon 15 sequence (Tavormina et al.
1995b).
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Figure 1 An affected individual is heterozygous for a sporadic
mutation disrupting a unique BbsI restriction site in FGFR3 exon 15.
PCR amplification of FGFR3 exon 15 was performed on DNA isolated
from fibroblasts and lymphoblast cell lines derived from patient 1 and
from lymphoblast cell lines derived from both her parents. Products
were digested with the restriction enzyme BbsI, analyzed on 2% aga-
rose gels, and visualized by ethidium bromide staining. BbsI digests
essentially all the 334-bp amplicon derived from the four parental
FGFR3 alleles but does not digest one allele of the amplicon derived
from the patient’s DNA. L patient lymphoblast cell line; F patient
fibroblast cell line.
Restriction Enzyme Analysis and Sequencing
PCR products were digested with the restriction en-
zyme BbsI (New England Biolabs), according to the
manufacturer’s instructions. Digested DNA was ana-
lyzed by electrophoresis on 2% agarose or 6% poly-
acrylamide gels using Tris-borate buffer and visualized
by staining with ethidium bromide. DNA sequencing
was performed on purified PCR products (Promega Wiz-
ard spin columns or electroelution) by means of the fluo-
rescent dideoxyterminator method of cycle sequencing
on a PE/ABI 373a automated DNA sequencer or by the
PCR products sequencing kit (USB), as described by the
manufacturer.
Construction of FGFR3 Mutants
Pairs of annealed oligonucleotides encoding each
Lys650 substitution (Lys650Glu and Lys650Met) were
inserted between the EcoRV site at amino acid 641 and
the AgeI site at amino acid 658 of the FGFR3 derivative
described elsewhere (Webster et al. 1996). All constructs
were confirmed by sequencing.
Immunoprecipitation and In Vitro Kinase Assays
National Institutes of Health (NIH) 3T3 cells were
transfected with 10 mg of each expression construct, by
means of a modified calcium phosphate transfection
method (Chen and Okayama 1987). Four hours after
refeeding, the medium was changed to serum-free Dul-
becco’s minimal essential medium. Twenty-four hours
later, cells were lysed in Nonidet P (NP)-40 lysis buffer
(20 mM Tris, pH 7.5; 137 mM NaCl; 1% NP-40; 5
mM EDTA; 10% glycerol; 10 mg/ml aprotinin; 1 mM
sodium orthovanadate) and immunoprecipitated with
antiserum specific for the C-terminus of FGFR3 (Santa
Cruz Biotechnology). Immune complexes were washed
once in 20 mM Tris, pH 7.5, and subjected to in vitro
kinase reactions in the presence of 40-ml kinase buffer
(20 mM Tris, pH 7.5; 10 mM MnCl2; 5mM MgCl2, 5
mCi g[32P]-ATP), for 15 min at 37C. Products were
washed extensively with NP-40 lysis buffer, electropho-
resed through a 7.5% SDS-PAGE gel, transferred to ni-
trocellulose, and exposed to x-ray film. In vitro kinase
activity was quantitated by laser scanning densitometry
of the autoradiograms. Similar quantitative results were
obtained from multiple experiments.
Immunoblotting
Filters prepared as described above were incubated
with anti-FGFR3 antiserum (Santa Cruz Biotechnology)
and horseradish peroxidase–conjugated goat antirabbit
IgG and developed by enhanced chemiluminescence
(Amersham), as per the manufacturer’s instructions.
Results
Identical mutations were discovered independently in
two unrelated patients in different laboratories. Patient
1 originally carried a diagnosis of achondroplasia and
was the only patient of 154 previously described, un-
related individuals with achondroplasia who did not
have an FGFR3 Gly380Arg mutation (Bellus et al.
1995b). It was noted in that report that this patient had
skeletal changes that were more severe than normally
observed in achondroplasia and exhibited other unusual
skeletal features (e.g., reverse bowing of the tibia and
fibula). An extensive search for FGFR3 mutations in this
patient, using exon-specific PCR primers covering 95%
of the coding sequence and heteroduplex analysis, was
unsuccessful. Because of her severe skeletal phenotype,
we next considered the possibility that she was a somatic
mosaic for a TD mutation. DNA was isolated from both
lymphoblast and fibroblast cell lines derived from this
patient and screened for the known TD1 and TD2 mu-
tations by means of PCR and digestion with specific
restriction enzymes. TD2 is caused by an ArG transition
at position 1948 that predicts a glutamic acid for lysine
substitution at codon 650 and disrupts a unique BbsI
restriction site in exon 15. A mutation disrupting this
BbsI site was found to be present in DNA isolated from
fibroblasts and lymphocytes from this patient and was
not present in either of her parents (fig. 1). Sequencing
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Figure 2 Mutation disrupting the BbsI site—an ArT transver-
sion at position 1949, predicting a Lys650Met substitution. The
FGFR3 PCR amplicon from patient 1 and one of her parents (control)
was sequenced with fluorescent dideoxynucleotides. The sequence of
the antisense strand is shown, and the nucleotide change in the patient’s
DNA is indicated. The predicted amino acid substitution in the sense
strand (lysine to methionine) is shown below, and the BbsI recognition
sequence is underlined.
of the FGFR3 exon 15 PCR amplicon derived from this
patient revealed that she was heterozygous for an ArT
transversion at position 1949, predicting a methionine
for lysine substitution at codon 650 (fig. 2). The FGFR3
A1949T (Lys650Met) mutation is unlikely to represent
a polymorphism, since it was not found on screening
1150 normal chromosomes by digestion with BbsI (data
not shown).
The other patient had phenotypic features consistent
with TD1 and died shortly after birth. A lymphoblastoid
cell line was made from a blood sample from this patient,
submitted to the International Skeletal Dysplasia Reg-
istry, and included in a large cohort of patients being
screened for FGFR3 mutations. Of 84 patients with a
clinical diagnosis of TD1 in whom an FGFR3 mutation
was found, this patient was the only one found to have
lost the FGFR3 exon 15 BbsI site on one allele (data
not shown). DNA sequencing demonstrated that the mu-
tation disrupting this restriction site in this patient was
also an ArT transversion at position 1949, predicting
a Lys650Met mutation (data not shown). Subsequently,
two additional unrelated patients with phenotypes sim-
ilar to that of the first patient were identified, screened
by BbsI digestion and sequencing, and found to be het-
erozygous for the Lys650Met mutation (data not
shown).
FGFR3 Lys650Met Phenotype
The clinical and radiographic features of these four
individuals with FGFR3 Lys650Met mutations fit within
the spectrum of the other FGFR3 skeletal dysplasias and
include several unique features. Detailed case reports and
a more extensive description of the clinical features are
to be reported elsewhere (G.A. Bellus, M.J. Bamshad,
K. Przylepa, J. Dorst, R. Lee, O. Hurko, E.W. Jabs,
C.J.R. Curry, W.R. Wilcox, R.S. Lachman, D.L. Rimoin,
C.A. Francomano, unpublished data). Although one pa-
tient had skeletal features similar to TD1 and died
shortly after birth, the other three patients survived and
have not needed prolonged ventilator support. Contin-
ued mechanical ventilation has been required in the few
reported cases of TD1 with extended survival (Mac-
Donald et al. 1989; Baker et al. 1997). The overall ap-
pearance of the surviving patients with the FGFR3
Lys650Met mutation is similar to that of patients with
achondroplasia, because of rhizomelia and megalence-
phaly. However, there is a much greater restriction in
growth, with stature being less than the 5th percentile
for achondroplasia (fig. 3a). Redundant skin folds of the
arms and legs, which are commonly seen during infancy
in achondroplasia, persisted into late childhood. Cran-
iosynostosis was not observed, and the skull shape is
reminiscent of achondroplasia and TD1 with severe mid-
face hypoplasia and frontal bossing (fig. 3a and b). Long-
bone growth is severely limited and there is femoral bow-
ing similar to that observed in TD1. In addition, three
of the four patients exhibited an unusual bowing of the
tibias, which occurs in the direction opposite that of the
femoral bowing (fig. 3a and c). Platyspondyly was ob-
served but was generally less severe than that observed
in TD1 or TD2 (fig. 3d).
During infancy, all the surviving patients developed
generalized seizures, which have been reasonably well
controlled with standard anticonvulsant medications.
Two of the surviving patients have undergone ventri-
culostomy placements for hydrocephalus and surgery to
relieve spinal and foramen magnum stenosis. The three
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Figure 3 Clinical and radiographic features of a patient with an FGFR3 Lys650Met mutation. A, Patient 1: age 4 years. B, Patient 1:
age 1 year. The lateral skull is shown. Note severe midface hypoplasia. C, Patient 1: age 1 d. The lower extremities are shown. Note severe
shortening of the long bones as well as femoral and tibial bowing. D, Patient 1: age 1 d. The lateral spine is shown. Note moderately severe
platyspondyly.
surviving patients exhibit severe mental retardation and
developmental delays. Magnetic resonance imaging eval-
uation of the brain has revealed several structural ab-
normalities that include thinning of the corpus callosum,
paucity of white matter with generalized brain atrophy,
and an abnormally large cerebellum.
Finally, during or shortly after infancy, the three sur-
viving patients developed acanthosis nigricans, which
has progressively spread over large areas of the body
surface. Insulin levels were tested and found to be nor-
mal in all three patients, indicating that the acanthosis
nigricans is not due to insulin resistance.
Lys650Met Mutation Activates FGFR3 Kinase Activity
The phenotype observed in our patients is different
from TD2 despite the fact that both mutations lead to
different amino acid substitutions at the same codon in
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Figure 4 FGFR3 Lys650Met results in strong activation of ki-
nase activity. NIH 3T3 cells were transfected with 10 mg of each ex-
pression construct, as described in the Material and Methods section,
and immunoprecipitated with FGFR3 antibody. Kinase assays were
performed on the immune complexes with g[32P]-labeled ATP, and the
products were analyzed by electrophoresis on a 7.5% SDS-PAGE gel
followed by transfer to nitrocellulose and exposure to x-ray film. The
phosphorylated FGFR3 protein is indicated by the arrow. Background
FGFR3 activity of untransfected NIH 3T3 cells is shown in the lane
labeled “mock.” The identity of the lower-molecular weight–labeled
product is not currently known. To control for the amount of receptor
loaded, duplicate filters prepared as above were incubated with anti-
FGFR3 antiserum and horseradish peroxidase–conjugated goat antir-
abbit IgG and visualized by enhanced chemiluminescence, as described
in Material and Methods.
the activation loop of the FGFR3 tyrosine kinase do-
main. It was therefore of interest to determine how the
Lys650Met mutation compared with the Lys650Glu mu-
tation in terms of its ability to activate the receptor ki-
nase. To assess the effect of the Lys650Met substitu-
tion on FGFR3 activity, constructs encoding wild-
type FGFR3, the TD2 mutation (Lys650Glu), or the
Lys650Met mutation were transiently transfected into
NIH 3T3 cells under the control of the cytomegalovirus
promoter. FGFR3 proteins were immunoprecipitated
from lysates of serum-deprived cells and subjected to in
vitro kinase assays in the presence of g[32P]-ATP. As
shown previously (Webster et al. 1996) (fig. 4), there is
a dramatic increase in the ligand-independent kinase ac-
tivity of the Lys650Glu mutant receptor compared with
the wild-type receptor, which is essentially inactive in
this assay. Scanning densitometry of the autoradiograms
reveals that the Lys650Glu mutation results in an ∼100-
fold stimulation of FGFR3 kinase activity over wild-type
FGFR3 and a 20-fold stimulation over that observed
with the Gly380Arg mutation found in achondroplasia
(Webster et al. 1996). The Lys650Met receptor exhibits
a further threefold increase in autophosphorylation ac-
tivity compared with the Lys650Glu receptor. This
greater activity does not occur because of increased ex-
pression of mutant receptor, since immunoblotting of
immunoprecipitates used in the kinase assay with
FGFR3-specific antiserum shows that similar amounts
of FGFR3 protein are present in each assay.
Discussion
We describe here a novel FGFR3 mutation (A1948T:
Lys650Met) causing a pleiotrophic phenotype that in-
cludes skeletal dysplasia, CNS dysfunction, and acan-
thosis nigricans. This mutation occurs within the FGFR3
tyrosine kinase domain activation loop and affects the
same codon altered in TD2 (Lys650Glu) but results in
a phenotype that is significantly different from TD2. The
FGFR3 Lys650Met mutation is compatible with survival
in three of the four patients we have identified and, there-
fore, calling this disorder a variant of TD seems inap-
propriate. Instead, we propose that the phenotypic syn-
drome associated with the FGFR3 Lys650Met mutation
be referred to as “severe achondroplasia with develop-
mental delay and acanthosis nigricans” (“SADDAN”).
SADDAN represents the seventh distinct genetic syn-
drome caused by an FGFR3 missense mutation (fig. 5).
Four phenotypic features (skeletal dysplasia, cranio-
synostosis, acanthosis nigricans, and CNS malforma-
tion) are associated with FGFR3 missense mutations in
humans, and some or all of these features may occur,
depending on the specific mutation. All four may occur
in TD1, although acanthosis nigricans is a late finding
and is observed only in rare cases with extended survival
(Baker et al. 1997). CNS malformations, including ab-
normal sulcation, polymicrogyria, neuronal heterotopia,
nuclear dysplasia, and abnormal neuronal bundles, have
been documented in TD with and without cloverleaf
skull (Wongmongkolrit et al. 1983; Ho et al. 1984; Shi-
gematsu et al. 1985). Of the four features, three are
present in SADDAN (Lys650Met) (skeletal dysplasia,
CNS malformation, and acanthosis nigricans) and three
are present in TD2 (Lys650Glu) (skeletal dysplasia, CNS
malformation, and craniosynostosis). However, ex-
tended survival has not been reported in TD2, and it is
not known whether acanthosis nigricans would develop
later in these individuals. Two features (craniosynostosis
and acanthosis nigricans) are present in Crouzon syn-
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Figure 5 FGFR3 mutations associated with human genetic disorders. A schematic diagram of the FGFR3 protein is presented and the
locations of the known human missense mutations are indicated. Immunoglobulin-like loops in the extracellular domain are labeled I–III.
Standard single-letter amino acid abbreviations are used to indicate the location and nature of the mutations associated with each human
disorder. The nucleotide and amino acid sequence of part of the kinase activation loop is shown, and the locations of the nucleotide substitutions
in TD2 and SADDAN are indicated. The nucleotide and amino acid substitutions in SADDAN are underlined. ACH  achondroplasia; CAN
 Crouzon syndrome with acanthosis nigricans; NSC  nonsyndromic craniosynostosis; HCH  hypochondroplasia; TM  transmembrane
domain; TK-1  proximal tyrosine kinase domain (ATP binding); and TK-2  distal tyrosine kinase domain (substrate binding and catalytic).
References for the mutations listed are given in the Introduction.
drome with acanthosis nigricans (Ala391Glu), and
only one feature is associated with achondroplasia
(Gly380Arg) (skeletal dysplasia) and with hypochon-
droplasia (Asn540Lys) (skeletal dysplasia), although it
is suspected that individuals with hypochondroplasia
may have a higher incidence of mild CNS dysfunction
(Walker et al. 1971; G. A. Bellus, unpublished data).
Craniosynostosis and distal skeletal anomalies are var-
iable in the syndrome defined by the Pro250Arg muta-
tion (Muenke et al. 1997).
Why certain amino acid substitutions in the FGFR3
protein lead to different combinations of these four phe-
notypic features is not well understood. The degree of
long-bone dysplasia observed in SADDAN is variable
but is always more severe than typically seen in achon-
droplasia or TD2 and approaches the severity observed
in TD1. On the other hand, dysplasia of the axial skel-
eton (i.e., platyspondyly) in SADDAN appears to be less
severe than in TD1 or TD2. Our results from in vitro
transfection assays demonstrate that the SADDAN
FGFR3 Lys650Met mutation leads to higher levels of
ligand-independent FGFR3 autophosphorylation than
the TD2 Lys650Glu or achondroplasia Gly380Arg mu-
tations and are consistent with other in vitro studies that
have shown that FGFR3 mutations associated with
more-severe disturbances of long-bone growth result in
larger increases in constitutive receptor activity (Naski
et al. 1996; Webster et al. 1996). Considering these data
in conjunction with the FGFR3 knockout mouse, which
exhibits a phenotype of endochondral bone overgrowth
(Colvin et al. 1996; Deng et al. 1996), one may conclude
that FGFR3 may indeed function normally as a negative
regulator of endochondral bone growth and that in-
creasing amounts of FGFR3 tyrosine kinase activity lead
to progressively more-severe disturbances in growth.
The FGFR3 Lys650Glu mutation has been associated
with activation of STAT1 and expression of p21waf1/cip1
in chondrocytes and may initiate inappropriate cell cycle
arrest (Su et al. 1997). The FGFR3 Lys650Met mutation
may act in a similar manner and may lead to higher
levels of p21waf1/cip1 expression in endochondral growth
plates, resulting in more-complete cell cycle arrest. Al-
ternatively, increased intensity or duration of FGFR3
signaling by the Lys650Met mutation may cause acti-
vation or inhibition of other signaling pathways con-
trolling endonchondral bone growth.
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Insights into the mechanisms of other associated
FGFR3 phenotypic features (craniosynostosis, CNS mal-
formations, and acanthosis nigricans) are less apparent.
Synostosis of multiple sutures (cloverleaf skull defor-
mity) is seen uniformly in TD2, occasionally in TD1,
and not, as yet, in SADDAN. Acanthosis nigricans is
observed in conjunction with craniosynostosis, but not
skeletal dysplasia, in Crouzon syndrome with acanthosis
nigricans, and in conjunction with skeletal dysplasia, but
not craniosynostosis, in SADDAN. Malformations of
the CNS are severe in TD1 and TD2 yet compatible with
survival in SADDAN. FGFR3 is constitutively activated
in all these disorders, but there may be differences among
these mutations in the mechanism and intensity of re-
ceptor activation and/or activation of downstream sig-
naling molecules. The TD1 extracellular domain mu-
tations (e.g., Arg248Cys) create unpaired cysteines that
most likely function to induce ligand-independent di-
merization of mutant receptors permitting trans and/or
cis autophosphorylation of critical intracellular tyrosine
residues (Naski et al. 1996). These mutant receptors are
fully active and cannot be stimulated further by ligand.
In contrast, the TD2 Lys650Glu and achondroplasia
Gly380Arg mutations result in moderate levels of
FGFR3 kinase activation and can be stimulated fur-
ther by addition of FGF ligands (Naski et al. 1996). It
is also possible that the FGFR3 TD2 Lys650Glu and
SADDAN Lys650Met mutations may not require recep-
tor dimerization to activate the tyrosine kinase. The abil-
ity of a Xenopus TD2 equivalent mutation (XFGFR1:
Lys562Glu) to induce mesoderm in Xenopus embryos
is not inhibited by FGFR-dominant negative constructs
(which act by blocking dimerization of functional re-
ceptors), although mutations of XFGFR1 homologous
to TD1 and achondroplasia mutations are inhibited by
dominant negative constructs (Neilson and Freisel
1996).
X-ray crystallographic studies of the FGFR1 kinase
domain (Mohammadi et al. 1996b) and FGFR3 muta-
genesis studies (Webster et al. 1996) provide some ad-
ditional insights into the effects of the FGFR3 Lys650Glu
and Lys650Met mutations on receptor kinase activity.
The FGFR3 Lys 650 codon is located within the kinase
activation loop and must play a critical role in main-
taining the unligated receptor kinase in a quiescent state.
Mutations that convert adjacent codons to glutamate
codons do not activate the kinase, and two highly con-
served adjacent tyrosine residues (Tyr 647 and Tyr 648),
whose equivalents are normally critical for ligand-de-
pendent activation of the FGFR1 kinase domain, are not
required for activation of the FGFR3 kinase when a
Lys650Glu mutation is present (Webster et al. 1996).
Mohammadi et al. (1996a) proposed that the FGFR3
Lys650Glu substitution may stabilize the kinase acti-
vation loop in an active conformation, thereby permit-
ting substrate interaction with the kinase-active site. Our
results suggest that a methionine substitution may have
a more dramatic effect than the glutamate substitution
in either stabilizing the active conformation or desta-
bilizing the quiescent conformation of the kinase acti-
vation loop.
A striking and unexplained difference between TD2
and SADDAN is the common occurrence of severe cran-
iosynostosis in the former and not in the latter. It is
possible that there is a threshold effect and that cran-
iosynostosis does not occur if there is too much or too
little constitutive activation of the FGFR3 kinase. An
alternate explanation is that FGFR3 receptors (or trans-
lation products of FGFR3 mRNA splicing isoforms)
with either mutation differentially activate other FGFRs
or lead to activation or inhibition of different down-
stream signaling pathways. Different amino acid sub-
stitutions at this critical residue may alter the binding
affinity of other substrate-signaling molecules so as to
phosphorylate an inappropriate substrate or fail to phos-
phorylate an appropriate one. Another possibility is that
these mutations may differentially interfere with the abil-
ity of tyrosine phosphatases to down-regulate receptor
signaling.
Much still needs to be learned before we fully under-
stand the molecular and developmental effects of these
and other FGFR3 mutations. More patients with
Lys650Met mutations will need to be evaluated to de-
termine the full spectrum of the SADDAN phenotype.
Further studies with transfected mutant constructs and
transgenic mice will be helpful in sorting out FGFR3
signaling pathways and how they are affected by specific
FGFR3 mutations.
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